Endometrial Hyperplasia: What Is Thickening of the Uterine Lining?
Endometrial hyperplasia is a condition commonly known as thickening of the uterine lining. The inner lining of the uterus is called the endometrium. During the menstrual cycle, this tissue thickens under the influence of hormones and is shed as menstrual bleeding if pregnancy does not occur.
In some cases, however, the endometrium may become thicker than expected and may grow in an irregular way. This condition is called endometrial hyperplasia. In many patients, it is a benign condition. However, some types may increase the risk of developing endometrial cancer in the future. For this reason, accurate diagnosis, appropriate treatment, and regular follow-up are important.
Why does the uterine lining become thickened?
The endometrium is mainly influenced by two hormones: estrogen and progesterone.
Estrogen stimulates the growth and thickening of the uterine lining. Progesterone balances this effect and helps the endometrium mature in an orderly way. If the endometrium is exposed to estrogen for a long time without enough progesterone effect, it may become excessively thickened.
This may occur in conditions such as:
Irregular or absent ovulation
Polycystic ovary syndrome
Obesity
Perimenopause
Long intervals without menstrual periods
Estrogen-only hormone therapy
Tamoxifen use
Diabetes, insulin resistance, or metabolic risk factors
Family history of endometrial, ovarian, or bowel cancer
Is every thickened uterine lining dangerous?
No. A thickened endometrium on ultrasound does not automatically mean cancer. Endometrial thickness may vary depending on age, the day of the menstrual cycle, menopausal status, medications, and other medical conditions.
The important questions are:
Why is the endometrium thickened?
Are there abnormal cellular changes called atypia?
Endometrial hyperplasia is generally classified into two main groups.
1. Endometrial hyperplasia without atypia
In this type, the endometrial cells have increased in number, but there are no significant abnormal cellular changes. Endometrial hyperplasia without atypia often responds well to treatment and, in selected cases, may even regress with careful observation and risk factor management.
The risk of progression to cancer is low, but the condition should not be ignored. Persistent abnormal bleeding, ongoing risk factors, or lack of improvement during follow-up may require a change in the treatment plan.
2. Atypical endometrial hyperplasia / EIN
Atypical endometrial hyperplasia is now often discussed together with the term EIN, which stands for endometrial intraepithelial neoplasia. In this condition, the cells show more significant abnormalities, and the risk of progression to endometrial cancer is higher.
For this reason, atypical hyperplasia requires a more careful approach than hyperplasia without atypia. Treatment planning depends on the patient’s age, desire for future pregnancy, suitability for surgery, and associated risk factors.
What symptoms may suggest endometrial hyperplasia?
The most common symptom of endometrial hyperplasia is abnormal uterine bleeding.
Medical evaluation is recommended in the following situations:
Menstrual bleeding that is heavier than usual
Periods lasting longer than normal
Bleeding between periods
Irregular, frequent, or unexpected bleeding
Bleeding after a long period without menstruation
Any vaginal bleeding after menopause
Even light spotting after menopause
One particularly important question is:
Is bleeding after menopause normal?
No. Bleeding after menopause is not considered normal, even if it is very light. Postmenopausal bleeding does not always mean cancer. It may be caused by polyps, thinning of the vaginal or uterine tissues, medications, or other benign conditions. However, endometrial disease must be ruled out.
How is endometrial hyperplasia diagnosed?
Endometrial hyperplasia cannot be diagnosed with ultrasound alone. Ultrasound can show the thickness and appearance of the uterine lining, but it cannot show the cellular structure.
A definite diagnosis usually requires an endometrial biopsy, which means taking a tissue sample from the uterine lining.
The main diagnostic methods include:
Transvaginal ultrasound
A transvaginal ultrasound allows evaluation of the uterus, ovaries, and endometrium. The thickness of the uterine lining is measured. The scan may also show polyps, fibroids, fluid inside the uterus, or irregular areas within the endometrium.
In women of reproductive age, endometrial thickness changes throughout the menstrual cycle. Therefore, a single measurement does not always indicate disease. After menopause, however, endometrial thickness is interpreted more cautiously, especially if bleeding is present.
Endometrial biopsy
An endometrial biopsy involves taking a small tissue sample from the lining of the uterus. It can often be performed in an outpatient clinic. The sample is then examined by a pathologist.
The pathology report helps answer important questions:
Is hyperplasia present?
If present, is it with or without atypia?
Is there any evidence of cancer?
Is there an endometrial polyp or another endometrial condition?
Hysteroscopy
Hysteroscopy is a procedure in which a thin camera is used to look inside the uterus. It is especially useful when there is suspicion of a polyp, focal thickening, irregular areas, or when previous biopsy results are insufficient.
During hysteroscopy, targeted biopsies can be taken from suspicious areas. If a polyp is found, it may often be removed during the same procedure.
Does every patient need the same treatment?
No. Treatment depends on the type of hyperplasia, the patient’s age, menopausal status, desire for future pregnancy, bleeding symptoms, risk factors, and pathology results.
The main goals of treatment are to:
Control abnormal bleeding
Reverse the thickening of the uterine lining
Reduce the risk of endometrial cancer
Consider the patient’s fertility wishes
Lower the risk of recurrence
Treatment of endometrial hyperplasia without atypia
In some patients with hyperplasia without atypia, careful observation and management of risk factors may be appropriate. However, patients with symptoms, persistent risk factors, or no improvement during follow-up usually require progesterone-based treatment.
Progesterone treatment may be given in two main ways.
Intrauterine progesterone system
A levonorgestrel-releasing intrauterine system, often known as a hormonal intrauterine device, is considered one of the preferred treatment options for many patients with endometrial hyperplasia without atypia. It delivers progesterone directly to the uterine lining. It may reduce bleeding, help the endometrium become thinner, and provide long-term protection.
Oral progesterone treatment
Some patients may be treated with oral progesterone medication. These treatments should be used regularly and for an adequate duration. The type, dose, and length of treatment should be determined by the physician according to the patient’s individual condition.
Treatment usually continues for several months, and the response is assessed with repeat biopsy.
Why is weight management important?
Fat tissue can contribute to hormonal processes that increase estrogen effect in the body. Therefore, overweight and obesity may increase the risk of endometrial hyperplasia and may also increase the chance of recurrence after treatment.
Weight management, regular physical activity, treatment of insulin resistance, and control of metabolic conditions are important not only for general health but also for endometrial health.
Treatment of atypical endometrial hyperplasia / EIN
When atypical hyperplasia or EIN is diagnosed, management must be more cautious. This condition carries a higher risk of progression to endometrial cancer. In some patients, an early cancer may already be present within the uterus at the time of diagnosis.
For patients who have completed childbearing and are suitable for surgery, hysterectomy, which means removal of the uterus, is often recommended as definitive treatment.
However, in younger patients who wish to preserve fertility, or in patients who are not suitable for surgery, fertility-sparing treatment may be considered. This usually involves progesterone therapy, but close follow-up is essential. Repeat biopsies are required to confirm whether the condition is responding to treatment.
When is hysterectomy considered?
Hysterectomy is not the first treatment option for every patient with endometrial hyperplasia. Many patients with hyperplasia without atypia can be managed with medication and follow-up.
Surgery may be considered in situations such as:
Atypical hyperplasia / EIN
Completed childbearing
No regression despite medical treatment
Recurrence after treatment
Persistent bleeding
Inability to continue regular biopsy follow-up
Other coexisting uterine conditions
In postmenopausal patients, the extent of surgery, including whether the ovaries and fallopian tubes should also be removed, is planned individually.
How is follow-up performed after treatment?
Follow-up is as important as treatment. Endometrial hyperplasia may regress, persist, or recur in some patients.
In hyperplasia without atypia, repeat endometrial biopsy is usually performed at specific intervals. The aim is to confirm that the uterine lining has returned to normal on pathological examination. After two consecutive negative biopsies, follow-up may be reduced or discontinued in selected patients.
Patients at higher risk of recurrence may require longer follow-up. This may include patients with a high body mass index, those treated with oral progesterone, or those with persistent risk factors.
Patients receiving fertility-sparing treatment for atypical hyperplasia or EIN require much closer follow-up, often with repeat biopsies every few months.
What should be done if bleeding returns after treatment?
If abnormal bleeding returns after treatment has been completed and previous follow-up results were normal, the patient should be reassessed. This is especially important after menopause.
A previous diagnosis of endometrial hyperplasia means that any new episode of abnormal bleeding should be taken seriously.
Frequently asked questions
Is endometrial hyperplasia cancer?
No. Endometrial hyperplasia is not cancer. However, some types, especially atypical hyperplasia or EIN, carry a higher risk of developing into endometrial cancer. Therefore, the pathology result is very important.
My ultrasound showed a thickened endometrium. Do I immediately need a biopsy?
Not always. The decision depends on age, menstrual pattern, menopausal status, bleeding symptoms, endometrial thickness, and risk factors. If bleeding occurs after menopause, evaluation is more urgent and careful.
Is a hormonal intrauterine device suitable for everyone?
No. A hormonal intrauterine system is effective for many patients, but suitability depends on the shape of the uterus, presence of infection, cause of bleeding, patient preference, and other medical conditions.
Is endometrial biopsy painful?
Some patients feel only mild cramping, while others may experience more noticeable discomfort. Pain relief, local measures, sedation, or anesthesia options may be considered depending on the patient.
Can endometrial hyperplasia come back?
Yes. Endometrial hyperplasia may recur in some patients. Persistent risk factors, obesity, irregular ovulation, poor treatment adherence, or insufficient follow-up may increase the risk of recurrence.
When should I see a doctor?
You should consult a gynecologist if you experience:
Bleeding after menopause
Irregular or frequent bleeding
Bleeding between periods
Heavy or prolonged menstrual bleeding
Bleeding after a long time without periods
Recurrent bleeding after a previous diagnosis of endometrial hyperplasia
Bleeding irregularities together with risk factors such as polycystic ovary syndrome, obesity, or tamoxifen use
Conclusion
Endometrial hyperplasia, or thickening of the uterine lining, is often a manageable condition when properly evaluated. However, accurate diagnosis, identification of atypia, and an appropriate follow-up plan are essential.
Treatment is not the same for every patient. Some patients may only need observation, while others may require progesterone therapy, a hormonal intrauterine system, or surgery.
Postmenopausal bleeding, recurrent abnormal bleeding, or bleeding in the presence of risk factors should not be ignored. Early diagnosis and regular follow-up help reduce unnecessary anxiety and allow serious conditions to be detected at an early stage
